Institute for Integrative Therapies

04/23/2026

New research on ketamine therapy for treatment-resistant depression offers promising results for patients who haven't found relief with conventional treatments.

Learn more about how this innovative approach could transform mental health care.

04/22/2026

We’re grateful to WCCO Radio for featuring IIT Founder and CEO Dr. Manoj Doss in a thoughtful conversation about the rapidly evolving landscape of psychedelic medicine.

This is a significant moment for the field. In just the last 60 days:

• COMPASS Pathways reported two positive Phase 3 trials of psilocybin for treatment-resistant depression
• The White House announces an executive order directing the FDA to fast-track psychedelic review
• The FDA cleared the way for the first-ever U.S. human trials of ibogaine

04/19/2026

The White House just signed an Executive Order on psychedelic medicines— a major shift in mental health treatment policy.

This order directs federal agencies to accelerate the development and approval of psychedelic-based treatments for serious mental illness including PTSD, treatment-resistant depression, and severe anxiety.

Key actions directed:
🔬 Prioritize psychedelic clinical trials
⚡ Fast-track FDA breakthrough therapies
📋 Review insurance coverage for approved treatments

The science is compelling: MDMA-assisted therapy for PTSD and psilocybin for treatment-resistant depression have shown remarkable results in peer-reviewed studies.

While the field evolves, IIT offers ketamine therapy as current evidence-based options.

IIT is also the only clinic in Minnesota that is an active psychedelic medicine clinical trial site. We are working with the leaders in this field to provide access as well.

Learn more at iit-mn.com. Link in our bio.

03/05/2026

The EMBRACE Clinical Research Study is now enrolling for a trial at the Institute for Integrative Therapies. The EMBRACE study is researching an investigational psychedelic substance, combined with psychological support into reduction in symptoms of Major Depressive Disorder (MDD).

We're excited to announce another clinical trial at our clinic and bring this important research to Minnesota.

02/12/2026

IIT is happy to announce that our trial site is seeking participants for this clinical trial.

The Elumina study is researching an investigational medicine that may offer a short- term treatment plan to improve depression symptoms.

If you're interested in this trial or any other clinical trial at IIT, reach out to see if you're eligible!

02/10/2026

IIT has been selected as a clinical-trial site for atai Beckley’s VLS-01-203 study—the first DMT study in Minnesota for people living with treatment-resistant depression.

VLS-01 is a novel buccal-film form of DMT, and represents a significant step forward in evidence-based psychedelic medicines for those suffering with TRD that haven't responded to the conventional treatments.

Being part of this landmark trial strengthens IIT’s role as a Midwest leader in psychedelic-medicine research—and, most important, gives Minnesotans early access to tomorrow’s breakthroughs.

11/20/2025

Proud to share that IIT has been selected as a clinical trial site for Cybin’s EMBRACE and EXTEND psilocin studies.

The Institute for Integrative Therapies (IIT), Minnesota’s leading psychedelic medicine clinic, is proud to announce its official selection as a clinical trial

09/16/2025

We are seeking a dedicated and detail-oriented Clinical Research Coordinator (CRC) to support the ex*****on of a psychedelic medicine clinical trial.

Apply now! Details on how to apply are on our website 👉

We are seeking a dedicated and detail-oriented Clinical Research Coordinator (CRC) to support the ex*****on of a psychedelic medicine clinical trial. The CRC will play a key role in ensuring study operations adhere to Good Clinical Practice (GCP), regulatory requirements, and protocol guidelines. Th...

07/25/2025

IIT has officially launched its participation in the global Phase 3 COMPASS Pathways clinical trial studying psilocybin therapy for treatment-resistant depression. We’re honored to be one of a select group of sites in the world contributing to this historic research.

This trial represents the most advanced clinical investigation of psilocybin for depression to date and has the potential to reshape how we treat severe mental illness. It’s also a major milestone for IIT, which began as a ketamine-assisted psychotherapy clinic and has now expanded into a full-scale psychedelic medicine research company.

IIT launches psilocybin depression trial as part of COMPASS Pathways’ global Phase 3 study on treatment-resistant depression.

04/25/2025

Ketamine is a catalyst for change. Move beyond symptom management and start living better. Our infusion program is physician-guided, helping you to understand your unique story and unlock deeper healing. We're here to support your journey.

12/24/2024

Join Our Innovative Integrative Specialty Clinic! The licensed Therapist position is open!

Gain experience in working as a psilocybin facilitator and with psychedelic therapies in a clinical trial.

We are seeking a compassionate and dedicated Therapist to join our team. The ideal candidate will have a strong commitment to high-quality patient care and experience in various therapeutic modalities.

11/15/2024

We’re expanding our access to care at The Institute for Integrative Therapies!

We now accept Cigna and Aetna insurance as part of our commitment to bringing affordable treatments to the larger community.

The Institute for Integrative Therapies is dedicated to the advancement of psychedelics in the field